SG11201400989TA - 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh - Google Patents
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idhInfo
- Publication number
- SG11201400989TA SG11201400989TA SG11201400989TA SG11201400989TA SG11201400989TA SG 11201400989T A SG11201400989T A SG 11201400989TA SG 11201400989T A SG11201400989T A SG 11201400989TA SG 11201400989T A SG11201400989T A SG 11201400989TA SG 11201400989T A SG11201400989T A SG 11201400989TA
- Authority
- SG
- Singapore
- Prior art keywords
- oxazolidin
- pyrimidin
- inhibitors
- ones
- mutant idh
- Prior art date
Links
- DPXAMRSETFKEGX-UHFFFAOYSA-N O=C1OCCN1C1=CC=NC=N1 Chemical class O=C1OCCN1C1=CC=NC=N1 DPXAMRSETFKEGX-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161539553P | 2011-09-27 | 2011-09-27 | |
PCT/IB2012/055133 WO2013046136A1 (fr) | 2011-09-27 | 2012-09-26 | 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201400989TA true SG11201400989TA (en) | 2014-04-28 |
Family
ID=47178237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201400989TA SG11201400989TA (en) | 2011-09-27 | 2012-09-26 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
Country Status (31)
Country | Link |
---|---|
US (1) | US8957068B2 (fr) |
EP (1) | EP2771337B1 (fr) |
JP (1) | JP6026544B2 (fr) |
KR (1) | KR20140069235A (fr) |
CN (1) | CN103958506B (fr) |
AP (1) | AP3907A (fr) |
AR (1) | AR088175A1 (fr) |
AU (1) | AU2012313888B2 (fr) |
BR (1) | BR112014007310A2 (fr) |
CA (1) | CA2849995A1 (fr) |
CL (1) | CL2014000746A1 (fr) |
CO (1) | CO6920291A2 (fr) |
CR (1) | CR20140143A (fr) |
CU (1) | CU24269B1 (fr) |
DO (1) | DOP2014000058A (fr) |
EA (1) | EA025183B1 (fr) |
ES (1) | ES2645968T3 (fr) |
GE (1) | GEP20166432B (fr) |
GT (1) | GT201400057A (fr) |
IL (1) | IL231786A (fr) |
MA (1) | MA35452B1 (fr) |
MX (1) | MX342326B (fr) |
NI (1) | NI201400026A (fr) |
PE (1) | PE20141581A1 (fr) |
SG (1) | SG11201400989TA (fr) |
TN (1) | TN2014000128A1 (fr) |
TW (1) | TWI547493B (fr) |
UA (1) | UA111503C2 (fr) |
UY (1) | UY34352A (fr) |
WO (1) | WO2013046136A1 (fr) |
ZA (1) | ZA201402144B (fr) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
WO2013134079A1 (fr) * | 2012-03-05 | 2013-09-12 | Amgen Inc. | Composés d'oxazolidinone et leurs dérivés |
US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
MX2015012822A (es) * | 2013-03-14 | 2016-05-31 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante. |
PE20151939A1 (es) * | 2013-03-14 | 2016-01-08 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante |
WO2015003360A2 (fr) * | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Composés thérapeutiquement actifs et leurs méthodes d'utilisation |
US10376510B2 (en) * | 2013-07-11 | 2019-08-13 | Agios Pharmaceuticals, Inc. | 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer |
WO2015003355A2 (fr) * | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Composés thérapeutiquement actifs et leurs méthodes d'utilisation |
US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
WO2015010297A1 (fr) * | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc. | Composés thérapeutiquement actifs et leurs méthodes d'utilisation |
AU2014316682B2 (en) | 2013-09-06 | 2018-11-22 | Aurigene Discovery Technologies Limited | 1,2,4-oxadiazole derivatives as immunomodulators |
WO2015127172A1 (fr) * | 2014-02-20 | 2015-08-27 | Agios Pharmaceuticals, Inc. | Composés thérapeutiquement actifs et leurs procédés d'utilisation |
WO2015154064A2 (fr) | 2014-04-04 | 2015-10-08 | Del Mar Pharmaceuticals | Utilisation de dianhydrogalactitol et de leurs analogues ou dérivés dans le traitement du carcinome non à petites cellules des poumons et du cancer des ovaires |
PE20170303A1 (es) * | 2014-06-17 | 2017-04-19 | Chiesi Farm Spa | Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas |
CA2961811C (fr) | 2014-09-19 | 2021-11-02 | Forma Therapeutics, Inc. | Derive de pyridinylquinolinone en tant qu'inhibiteurs de l'isocitrate deshydrogenase mutante |
MX2017003637A (es) | 2014-09-19 | 2018-01-24 | Forma Therapeutics Inc | Derivados de fenil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh). |
ME03776B (fr) | 2014-09-19 | 2021-04-20 | Forma Therapeutics Inc | Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase |
ES2768694T3 (es) * | 2014-09-19 | 2020-06-23 | Forma Therapeutics Inc | Composiciones de quinolinona pirimidinas como inhibidores de isocitrato dehidrogenasa mutante |
RU2704008C2 (ru) | 2014-09-22 | 2019-10-23 | Нэшнл Хелс Ресерч Инститьютс | Гетероциклические соединения и их применение |
EP3202766B1 (fr) * | 2014-10-01 | 2019-12-25 | Daiichi Sankyo Company, Limited | Dérivé d'isoxazole comme inhibiteur de l'isocitrate déshydrogénase 1 muté |
EP3209660B1 (fr) * | 2014-10-23 | 2020-06-17 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | 1-cyclohexyl -2-phénylaminobenzimidazoles en tant qu'inhibiteurs de midh1 dans le traitement de tumeurs |
WO2016089833A1 (fr) | 2014-12-05 | 2016-06-09 | Merck Sharp & Dohme Corp. | Nouveaux composés tricycliques comme inhibiteurs d'enzymes idh mutantes |
US10703746B2 (en) | 2014-12-22 | 2020-07-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mutant IDH1 inhibitors useful for treating cancer |
CN107427477B (zh) | 2015-03-10 | 2021-11-26 | 奥瑞基尼探索技术有限公司 | 作为免疫调节剂的1,2,4-噁二唑和噻二唑化合物 |
KR20170123317A (ko) * | 2015-03-10 | 2017-11-07 | 오리진 디스커버리 테크놀로지스 리미티드 | 면역조절제로서의 3-치환된-1,2,4-옥사다이아졸 및 티아다이아졸 화합물 |
US10407419B2 (en) | 2015-04-21 | 2019-09-10 | Forma Therapeutics, Inc. | Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors |
US10294206B2 (en) | 2015-04-21 | 2019-05-21 | Forma Tm2, Inc. | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
TWI681959B (zh) * | 2015-06-09 | 2020-01-11 | 日商第一三共股份有限公司 | 作為變異型異檸檬酸脫氫酶1阻礙劑之異噁唑衍生物 |
US10179123B2 (en) | 2015-07-07 | 2019-01-15 | Bayer Pharma Aktiengesellschaft | 2-aryl- and 2-arylalkyl-benzimidazoles as mIDH1 inhibitors |
WO2017019429A1 (fr) * | 2015-07-27 | 2017-02-02 | Eli Lilly And Company | Coposés de 7-phényléthylamino -4 h-pyrimido [4,5-d] [1,3] oxazin-2-one et leur utilisation en tant qu'inhibiteurs de idh1 mutante |
TW201708193A (zh) | 2015-07-27 | 2017-03-01 | 拜耳製藥公司 | 突變之異檸檬酸脫氫酶idh1 r132h之抑制劑 |
TWI620748B (zh) | 2016-02-05 | 2018-04-11 | National Health Research Institutes | 氨基噻唑化合物及其用途 |
WO2017140758A1 (fr) | 2016-02-19 | 2017-08-24 | Debiopharm International S.A. | Dérivés de 2-amino-4-(2-oxazolidinone-3-yl)-pyrimidine fusionnés avec un noyau hétéroaromatique à cinq chaînons en position 5,6 qui sont utiles dans le traitement de divers cancers |
CN107216312B (zh) | 2016-03-22 | 2023-08-01 | 上海海和药物研究开发股份有限公司 | 一种具有突变型idh抑制活性的化合物、其制备方法及用途 |
WO2017213910A1 (fr) | 2016-06-06 | 2017-12-14 | Eli Lilly And Company | Inhibiteurs de la idh1 mutante |
CA3045303C (fr) * | 2016-12-16 | 2022-05-17 | Eli Lilly And Company | Composes de 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one en tant qu'inhibiteurs d'idh1 et d'idh2 mutants |
CA3047136A1 (fr) | 2016-12-19 | 2018-06-28 | Isocure Biosciences Inc. | Inhibiteurs d'isocitrate deshydrogenases mutantes, compositions et procedes correspondants |
WO2019061324A1 (fr) | 2017-09-29 | 2019-04-04 | Curis Inc. | Formes cristallines d'immunomodulateurs |
AU2018346597B2 (en) | 2017-10-06 | 2023-07-13 | Forma Therapeutics, Inc. | Inhibiting Ubiquitin Specific Peptidase 30 |
BR112020006669A2 (pt) | 2017-10-11 | 2020-09-24 | Aurigene Discovery Technologies Limited | formas cristalinas de 1,2,4-oxadiazol 3-substituído |
US11873298B2 (en) | 2017-10-24 | 2024-01-16 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
BR112020008537A2 (pt) | 2017-11-03 | 2020-10-06 | Aurigene Discovery Technologies Limited | inibidores duplos de vias da tim-3 e da pd-1 |
JP7378395B2 (ja) | 2017-11-06 | 2023-11-13 | オーリジーン オンコロジー リミテッド | 免疫調節のためのコンジョイントセラピー |
CN110407855A (zh) * | 2018-04-26 | 2019-11-05 | 上海嗣新生物科技有限公司 | 2-氨基嘧啶啶衍生物及其制备方法和用途 |
US10532047B2 (en) | 2018-05-16 | 2020-01-14 | Forma Therapeutics, Inc. | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
US11013734B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
US11576906B2 (en) | 2018-05-16 | 2023-02-14 | Forma Therapeutics, Inc. | Inhibiting mutant IDH-1 |
US11013733B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
US11311527B2 (en) | 2018-05-16 | 2022-04-26 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
KR102584855B1 (ko) * | 2018-06-26 | 2023-10-05 | 케이피씨 파마슈티컬스 인코포레이티드 | 벤즈이미다졸 유도체 및 idh1 억제제로서의 이의 용도 |
BR112021003620A2 (pt) | 2018-10-05 | 2021-05-18 | Forma Therapeutics, Inc. | pirrolinas fundidas que atuam como inibidoras da protease específica para a ubiquitina 30 (usp30) |
KR20220003173A (ko) * | 2019-03-22 | 2022-01-07 | 유마니티 테라퓨틱스, 인크. | 화합물 및 이의 용도 |
CN111825666B (zh) * | 2019-04-23 | 2024-03-08 | 上海仕谱生物科技有限公司 | 二聚或多聚体形式的突变型idh抑制剂 |
EP4319766A1 (fr) * | 2021-04-08 | 2024-02-14 | Memorial Sloan Kettering Cancer Center | Inhibition de la nadk2 dans le cancer et les troubles fibrotiques |
US11746115B2 (en) | 2021-08-13 | 2023-09-05 | Eli Lilly And Company | Solid forms of 7-[[(1S)-1-[4-[(1S)-2-cyclopropyl-1-(4-prop-2-enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4H-pyrimido[4,5-d][1,3]oxazin-2-one |
Family Cites Families (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB581334A (en) | 1943-09-29 | 1946-10-09 | Francis Henry Swinden Curd | New pyrimidine compounds |
JPS4921148B1 (fr) | 1970-12-28 | 1974-05-30 | ||
JPS4921149A (fr) | 1972-06-15 | 1974-02-25 | ||
DE2341925A1 (de) | 1973-08-20 | 1975-03-06 | Thomae Gmbh Dr K | Neue pyrimidinderivate und verfahren zu ihrer herstellung |
AT340933B (de) | 1973-08-20 | 1978-01-10 | Thomae Gmbh Dr K | Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze |
US4994386A (en) | 1987-07-13 | 1991-02-19 | Pharmacia Diagnostics, Inc. | Production of HBLV virus in the HSB-2 cell line |
US4929726A (en) | 1988-02-09 | 1990-05-29 | Georgia State University Foundation, Inc. | Novel diazines and their method of preparation |
EP0330263A1 (fr) | 1988-02-25 | 1989-08-30 | Merck & Co. Inc. | Pipérazinylalkylpyrimidines comme agents hypoglycémiques |
GB9012311D0 (en) | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
EP0489925B1 (fr) | 1990-07-03 | 1996-06-12 | Mitsui Petrochemical Industries, Ltd. | Compose de pyrimidine et sel pharmaceutiquement acceptable de ce compose |
DE69624437T2 (de) | 1995-04-13 | 2003-08-07 | Taiho Pharmaceutical Co Ltd | 4,6-diarylpyrimidin-derivate und deren salze |
JP3734907B2 (ja) | 1996-12-19 | 2006-01-11 | 富士写真フイルム株式会社 | 現像処理方法 |
ES2213286T3 (es) | 1997-07-24 | 2004-08-16 | Zenyaku Kogyo Kabushiki Kaisha | Compuestos heterociclicos y agente antitumoral que los contiene como ingredientes activos. |
JPH11158073A (ja) | 1997-09-26 | 1999-06-15 | Takeda Chem Ind Ltd | アデノシンa3拮抗剤 |
US6440965B1 (en) | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
US6150362A (en) | 1997-12-12 | 2000-11-21 | Henkin; Jack | Triazine angiogenesis inhibitors |
DK0930302T3 (da) | 1998-01-16 | 2003-07-21 | Hoffmann La Roche | Benzosulfonderivater |
US7045519B2 (en) | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
ATE274510T1 (de) | 1998-06-19 | 2004-09-15 | Chiron Corp | Glycogen synthase kinase 3 inhibitoren |
CA2359680A1 (fr) | 1999-01-22 | 2000-07-27 | David M. Armistead | Inhibiteurs de kinase |
US6495558B1 (en) | 1999-01-22 | 2002-12-17 | Amgen Inc. | Kinase inhibitors |
JP2003503351A (ja) | 1999-06-30 | 2003-01-28 | メルク エンド カムパニー インコーポレーテッド | Srcキナーゼ阻害化合物 |
US6498165B1 (en) | 1999-06-30 | 2002-12-24 | Merck & Co., Inc. | Src kinase inhibitor compounds |
WO2001000214A1 (fr) | 1999-06-30 | 2001-01-04 | Merck & Co., Inc. | Composes inhibiteurs de la kinase src |
PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
EP1196411B1 (fr) | 1999-07-15 | 2003-09-17 | Pharmacopeia, Inc. | Antagonistes du recepteur b1 de la bradykinine |
JP2001089452A (ja) | 1999-09-22 | 2001-04-03 | Sankyo Co Ltd | ピリミジン誘導体 |
GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
AU3704101A (en) | 2000-02-17 | 2001-08-27 | Amgen Inc | Kinase inhibitors |
NZ521068A (en) | 2000-03-29 | 2005-04-29 | Cyclacel Ltd | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders |
JP3649395B2 (ja) | 2000-04-27 | 2005-05-18 | 山之内製薬株式会社 | 縮合ヘテロアリール誘導体 |
CN1657523A (zh) | 2000-04-28 | 2005-08-24 | 田边制药株式会社 | 环状化合物 |
JP2004501913A (ja) | 2000-06-23 | 2004-01-22 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | ヘテロアリール−フェニル置換Xa因子阻害剤 |
JP2004514656A (ja) | 2000-09-06 | 2004-05-20 | カイロン コーポレイション | グリコゲンシンターゼキナーゼ3のインヒビター |
EP1317450B1 (fr) | 2000-09-15 | 2006-11-22 | Vertex Pharmaceuticals Incorporated | Composes de pyrazole utiles comme inhibiteurs de proteine kinase |
SE0004053D0 (sv) | 2000-11-06 | 2000-11-06 | Astrazeneca Ab | N-type calcium channel antagonists for the treatment of pain |
NZ526471A (en) | 2000-12-21 | 2005-08-26 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
WO2002062766A2 (fr) | 2001-02-07 | 2002-08-15 | Millennium Pharmaceuticals, Inc. | Composes de liaison au recepteur de la melanocortine-4 et procedes d'utilisation de tels composes |
US20030130264A1 (en) | 2001-02-16 | 2003-07-10 | Tularik Inc. | Methods of using pyrimidine-based antiviral agents |
EP1395561A1 (fr) | 2001-05-25 | 2004-03-10 | Boehringer Ingelheim Pharmaceuticals Inc. | Composes de carbamate et d'oxamide inhibant la production de cytokine |
US7087614B2 (en) | 2001-06-19 | 2006-08-08 | Bristol-Myers Squibb Co. | Pyrimidine inhibitors of phosphodiesterase (PDE) 7 |
US6603000B2 (en) | 2001-07-11 | 2003-08-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Synthesis for heteroarylamine compounds |
WO2003030909A1 (fr) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- et 4-aminopyrimidines n-substituees par un noyau bicyclique utilisees comme inhibiteurs de kinases dans le traitement du cancer |
US7091343B2 (en) | 2002-03-15 | 2006-08-15 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
ES2289279T3 (es) | 2002-03-15 | 2008-02-01 | Vertex Pharmaceuticals Incorporated | Composiciones utiles como inhibidores de proteinquinasas. |
EP1485380B1 (fr) | 2002-03-15 | 2010-05-19 | Vertex Pharmaceuticals Incorporated | Azolylaminoazines inhibitrices des proteines kinases |
WO2003078426A1 (fr) | 2002-03-15 | 2003-09-25 | Vertex Pharmaceuticals, Inc. | Azolylaminoazines en tant qu'inhibiteurs de proteines kinases |
WO2004000820A2 (fr) | 2002-06-21 | 2003-12-31 | Cellular Genomics, Inc. | Monocycles aromatiques utilises comme modulateurs de la kinase |
JP2006510597A (ja) | 2002-09-27 | 2006-03-30 | メルク エンド カムパニー インコーポレーテッド | 置換ピリミジン類 |
JP2006515274A (ja) | 2002-10-08 | 2006-05-25 | マサチューセッツ・インスティテュート・オブ・テクノロジー | コレステロール輸送の調節のための化合物 |
US7223870B2 (en) | 2002-11-01 | 2007-05-29 | Pfizer Inc. | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction |
AU2003295776B2 (en) | 2002-11-21 | 2011-05-12 | Novartis Vaccines And Diagnostics, Inc. | 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer |
JP2006521357A (ja) | 2003-03-24 | 2006-09-21 | メルク エンド カムパニー インコーポレーテッド | ナトリウムチャンネル遮断薬としてのビアリール置換6員複素環化合物 |
US20050014753A1 (en) | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
WO2004092196A2 (fr) | 2003-04-09 | 2004-10-28 | Exelixis, Inc. | Modulateurs de tie-2 et procedes d'utilisation |
CA2531490A1 (fr) | 2003-07-15 | 2005-02-03 | Neurogen Corporation | Analogues de pyrimidine-4-ylamine substitues constituant des ligands des recepteurs vanilloides |
CA2531619A1 (fr) | 2003-07-16 | 2005-01-27 | Neurogen Corporation | Analogues de biaryl piperazinyl-pyridine |
AR045944A1 (es) | 2003-09-24 | 2005-11-16 | Novartis Ag | Derivados de isoquinolina 1.4-disustituidas |
JP2007507529A (ja) * | 2003-09-30 | 2007-03-29 | サイオス・インコーポレーテツド | 複素環式アミドおよびスルホンアミド |
AU2005232745A1 (en) | 2004-04-13 | 2005-10-27 | Astellas Pharma Inc. | Polycyclic pyrimidines as potassium ion channel modulators |
GB0415365D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
GB0415364D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
MY145822A (en) | 2004-08-13 | 2012-04-30 | Neurogen Corp | Substituted biaryl piperazinyl-pyridine analogues |
JP2008521900A (ja) | 2004-11-30 | 2008-06-26 | アムジエン・インコーポレーテツド | キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用 |
WO2006065872A1 (fr) | 2004-12-13 | 2006-06-22 | Neurogen Corporation | Analogues de piperazinyl-pyridine |
CA2590586A1 (fr) | 2004-12-13 | 2006-07-06 | Neurogen Corporation | Analogues de biaryle substitues |
PL1836169T3 (pl) | 2004-12-28 | 2012-07-31 | Kinex Pharmaceuticals Llc | Kompozycje i sposoby leczenia zaburzeń związanych z proliferacją komórek |
AU2006206246A1 (en) | 2005-01-19 | 2006-07-27 | Neurogen Corporation | Heteroaryl substituted piperazinyl-pyridine analogues |
CA2599320A1 (fr) | 2005-02-25 | 2006-08-31 | Kudos Pharmaceuticals Limited | Composes |
TW200716594A (en) | 2005-04-18 | 2007-05-01 | Neurogen Corp | Substituted heteroaryl CB1 antagonists |
GB2431156A (en) | 2005-10-11 | 2007-04-18 | Piramed Ltd | 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase |
CA2635997A1 (fr) | 2006-01-11 | 2007-07-19 | Astrazeneca Ab | Derives de morpholinopyrimidine et leur utilisation therapeutique |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
US7977336B2 (en) | 2006-12-28 | 2011-07-12 | Banyu Pharmaceutical Co. Ltd | Aminopyrimidine derivatives as PLK1 inhibitors |
CL2007003847A1 (es) * | 2006-12-28 | 2008-04-18 | Basf Ag | Compuestos derivados de pirimidinas 2,4,5 tri-sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento del cancer. |
ATE551334T1 (de) | 2007-02-06 | 2012-04-15 | Novartis Ag | Pi3-kinase-hemmer und verfahren zu ihrer verwendung |
US7957951B2 (en) | 2007-03-16 | 2011-06-07 | Robert Bosch Gmbh | Address translation system for use in a simulation environment |
BRPI0814818A2 (pt) | 2007-07-09 | 2019-09-10 | Astrazeneca Ab | composto, uso de um composto, métodos para produzir um efeito anti-proliferativo e um efeito inibitório de mtor quinase em uma animal de sangue quente, método para tratar doenças, e, composição farmacêutica |
WO2009066084A1 (fr) | 2007-11-21 | 2009-05-28 | F. Hoffmann-La Roche Ag | 2-morpholinopyrimidines et leur utilisation en tant qu'inhibiteurs de kinase pi3 |
KR20100131446A (ko) | 2008-03-05 | 2010-12-15 | 노파르티스 아게 | Egfr 의존성 질환 또는 egfr 족 구성원을 표적으로 하는 작용제에 대한 내성을 획득한 질환의 치료를 위한 피리미딘 유도체의 용도 |
CA2717948C (fr) | 2008-03-26 | 2016-09-06 | Novartis Ag | 5-imidazoquinoleines et derives de pyrimidine en tant que modulateurs puissants de processus angiogeniques controles par vegf |
US20110053907A1 (en) | 2008-03-27 | 2011-03-03 | Auckland Uniservices Limited | Substituted pyrimidines and triazines and their use in cancer therapy |
US8575338B2 (en) | 2008-04-09 | 2013-11-05 | Mitsubishi Tanabe Pharma Corporation | Pyrimidine, pyridine and triazine derivatives as maxi-K channel openers |
GB0815369D0 (en) | 2008-08-22 | 2008-10-01 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
JP2012506898A (ja) | 2008-10-31 | 2012-03-22 | ノバルティス アーゲー | ホスファチジルイノシトール−3−キナーゼ(PI3K)阻害剤とmTOR阻害剤との併用剤 |
GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
US8513242B2 (en) | 2008-12-12 | 2013-08-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
RU2535217C2 (ru) * | 2009-02-06 | 2014-12-10 | Ниппон Синяку Ко., Лтд. | Производные аминопиразина и лекарственные средства |
JP5747440B2 (ja) | 2009-02-06 | 2015-07-15 | 住友化学株式会社 | ヒドラジド化合物及びその有害生物防除用途 |
CN108524505A (zh) | 2009-03-13 | 2018-09-14 | 安吉奥斯医药品有限公司 | 用于细胞增殖相关病症的方法和组合物 |
WO2010120994A2 (fr) | 2009-04-17 | 2010-10-21 | Wyeth Llc | Composés d'uréido-aryl-pyrimidine et de carbamoylaryl-morpholino-pyrimidine, leur utilisation comme inhibiteurs de la kinase mtor et de la kinase pi-3, et leur synthèse |
PT2432767E (pt) | 2009-05-19 | 2013-07-25 | Dow Agrosciences Llc | Compostos e métodos para controlo de fungos |
ES2706185T3 (es) | 2009-07-07 | 2019-03-27 | Mei Pharma Inc | Pirimidinil y 1,3,5-triazinil bencimidazoles y sus usos en la terapia contra el cáncer |
WO2011017296A1 (fr) | 2009-08-04 | 2011-02-10 | Schering Corporation | Dérivés de pyrimidine 4,5,6-trisubstituée comme inhibiteurs du facteur ixa |
AR077999A1 (es) | 2009-09-02 | 2011-10-05 | Vifor Int Ag | Antagonistas de pirimidin y triazin-hepcidina |
TW201609747A (zh) | 2009-09-09 | 2016-03-16 | 阿維拉製藥公司 | Pi3激酶抑制劑及其用途 |
EP2509600B1 (fr) | 2009-12-09 | 2017-08-02 | Agios Pharmaceuticals, Inc. | Composés thérapeutiquement actifs destinés au traitement d'un cancer caractérisé par une mutation idh |
GB201004200D0 (en) | 2010-03-15 | 2010-04-28 | Univ Basel | Spirocyclic compounds and their use as therapeutic agents and diagnostic probes |
AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
US20130109643A1 (en) | 2010-05-10 | 2013-05-02 | The Johns Hopkins University | Metabolic inhibitor against tumors having an idh mutation |
ES2704862T3 (es) | 2010-07-16 | 2019-03-20 | Agios Pharmaceuticals Inc | Composiciones terapéuticamente activas y su método de uso |
CN103140479B (zh) | 2010-10-01 | 2015-04-08 | 诺华有限公司 | 制造嘧啶衍生物的方法 |
SG189019A1 (en) | 2010-10-18 | 2013-05-31 | Cerenis Therapeutics Holding Sa | Compounds, compositions and methods useful for cholesterol mobilisation |
GB201106829D0 (en) | 2011-04-21 | 2011-06-01 | Proximagen Ltd | Heterocyclic compounds |
MX2013009256A (es) | 2011-02-11 | 2013-12-09 | Dana Farber Cancer Inst Inc | Metodo para inhibir las celulas tumorales hamartoma. |
CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
BR112014004577A2 (pt) | 2011-09-01 | 2017-04-04 | Novartis Ag | inibidor pi3k para uso no tratamento de câncer ósseo ou para prevenção por metástase de células cancerosas primárias para os ossos |
WO2013052395A1 (fr) | 2011-10-06 | 2013-04-11 | Merck Sharp & Dohme Corp. | Inhibiteurs azétidines substitués en 1,3 de pde10 |
UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
SG11201406550QA (en) | 2012-05-16 | 2014-11-27 | Novartis Ag | Dosage regimen for a pi-3 kinase inhibitor |
RU2014154009A (ru) | 2012-06-06 | 2016-08-10 | Новартис Аг | Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания |
EP2885003B1 (fr) | 2012-08-16 | 2021-09-29 | Novartis AG | Combinaison de pi3k inhibiteur et de c-met inhibiteur |
WO2014064058A1 (fr) | 2012-10-23 | 2014-05-01 | Novartis Ag | Procédé amélioré pour la fabrication de 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-trifluorométhylpyridin-2-amine |
US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
CN103483345B (zh) | 2013-09-25 | 2016-07-06 | 中山大学 | Pi3k激酶抑制剂、包含其的药物组合物及其应用 |
CN103694218B (zh) | 2013-12-05 | 2016-04-27 | 中山大学 | 嘧啶化合物、pi3k抑制剂、包含pi3k抑制剂的药物组合物及应用 |
-
2012
- 2012-09-26 CN CN201280058052.3A patent/CN103958506B/zh not_active Expired - Fee Related
- 2012-09-26 ES ES12784701.0T patent/ES2645968T3/es active Active
- 2012-09-26 WO PCT/IB2012/055133 patent/WO2013046136A1/fr active Application Filing
- 2012-09-26 AU AU2012313888A patent/AU2012313888B2/en not_active Ceased
- 2012-09-26 BR BR112014007310A patent/BR112014007310A2/pt not_active IP Right Cessation
- 2012-09-26 AP AP2014007602A patent/AP3907A/en active
- 2012-09-26 CA CA2849995A patent/CA2849995A1/fr active Pending
- 2012-09-26 TW TW101135421A patent/TWI547493B/zh active
- 2012-09-26 PE PE2014000427A patent/PE20141581A1/es not_active Application Discontinuation
- 2012-09-26 UA UAA201403086A patent/UA111503C2/uk unknown
- 2012-09-26 JP JP2014532533A patent/JP6026544B2/ja not_active Expired - Fee Related
- 2012-09-26 MX MX2014003752A patent/MX342326B/es active IP Right Grant
- 2012-09-26 US US14/347,481 patent/US8957068B2/en active Active
- 2012-09-26 SG SG11201400989TA patent/SG11201400989TA/en unknown
- 2012-09-26 EA EA201490696A patent/EA025183B1/ru not_active IP Right Cessation
- 2012-09-26 GE GEAP201213450A patent/GEP20166432B/en unknown
- 2012-09-26 CU CUP2014000036A patent/CU24269B1/xx unknown
- 2012-09-26 KR KR1020147010827A patent/KR20140069235A/ko not_active Application Discontinuation
- 2012-09-26 EP EP12784701.0A patent/EP2771337B1/fr active Active
- 2012-09-27 AR ARP120103605A patent/AR088175A1/es unknown
- 2012-09-27 UY UY0001034352A patent/UY34352A/es not_active Application Discontinuation
-
2014
- 2014-03-24 ZA ZA2014/02144A patent/ZA201402144B/en unknown
- 2014-03-25 MA MA36849A patent/MA35452B1/fr unknown
- 2014-03-26 NI NI201400026A patent/NI201400026A/es unknown
- 2014-03-26 TN TNP2014000128A patent/TN2014000128A1/en unknown
- 2014-03-26 CL CL2014000746A patent/CL2014000746A1/es unknown
- 2014-03-27 CR CR20140143A patent/CR20140143A/es unknown
- 2014-03-27 CO CO14065647A patent/CO6920291A2/es active IP Right Grant
- 2014-03-27 IL IL231786A patent/IL231786A/en not_active IP Right Cessation
- 2014-03-27 GT GT201400057A patent/GT201400057A/es unknown
- 2014-03-27 DO DO2014000058A patent/DOP2014000058A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP3907A (en) | 3-Pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | |
HK1244183A1 (zh) | Ivacaftor的氘化衍生物 | |
HK1213251A1 (zh) | 作為突變 抑制劑的 -嘧啶- -基-噁唑烷- -酮化合物 | |
ZA201309561B (en) | Novel inhibitor compounds of phosphodiestarase type 10a | |
IL229830B (en) | Novel compinds as modulatord of gpr-119 | |
HUE047354T2 (hu) | Ivacaftor deuterizált származékai | |
EP2712362A4 (fr) | Fabrication de lacto-n-tétraose | |
EP2721020A4 (fr) | Composés inhibiteurs de métalloenzymes | |
IL228103A0 (en) | Amino-quinolines as kinase inhibitors | |
SI2670401T1 (sl) | Postopki uporabe inhibitorjev ALK | |
ZA201206456B (en) | Uses of dgati inhibitors | |
EP2685992A4 (fr) | Amino-quinoléines en tant qu'inhibiteurs de kinase | |
HK1199252A1 (en) | Inhibitors of nedd8-activating enzyme nedd8- | |
PL2753330T3 (pl) | Terapeutyczne zastosowania ektoiny | |
ME02167B (me) | Piridinil- i pirazinil-metiloksi-aril derivati korisni kao inhibitori tirozin kinaze slezine (syk) | |
ZA201402166B (en) | Compositions of efavirenz | |
EP2768481A4 (fr) | Compositions pour la réduction d'effets secondaires | |
GB201113815D0 (en) | Multi-photon isomerisation of transcombretastatins | |
EP2663322A4 (fr) | Nouvelles utilisations d'inhibiteurs de la cyclophiline | |
GB201104399D0 (en) | Novel inhibitors | |
GB201108347D0 (en) | Polymprphic form of compound |